See the DrugPatentWatch profile for tigecycline

Tigecycline: The Off-Patent Antibiotic Still Prescribed Despite the Odds

Tigecycline, a broad-spectrum antibiotic, was first approved by the US FDA in 2005. Initially, it was marketed as a treatment for complicated skin and skin structure infections (cSSSI), as well as community-acquired bacterial pneumonia (CABP). However, despite being off-patent since 2013, tigecycline remains a prescribed medication in many parts of the world. But what benefits keep it prescribed despite being off patent?

A Review of Tigecycline's Efficacy

Tigecycline's unique mechanism of action makes it an attractive option for treating a range of infections. It works by inhibiting protein synthesis, thereby preventing bacterial growth. This broad-spectrum activity allows it to be effective against a wide range of pathogens, including MRSA, VRE, and ESBL-producing bacteria.

Off-Patent but Not Off-the-Shelf

So, why is tigecycline still prescribed despite being off-patent? One reason is that it has a unique pharmacokinetic profile. Tigecycline has a long half-life, which allows for once-daily dosing. This convenience factor makes it an attractive option for patients who require extended treatment periods.

Cost-Effectiveness

Another reason tigecycline remains prescribed is its cost-effectiveness. According to a study published in the Journal of Antimicrobial Chemotherapy, tigecycline was found to be more cost-effective than other antibiotics in treating cSSSI and CABP. This is likely due to its ability to treat a range of pathogens, reducing the need for additional antibiotics and subsequent hospitalizations.

Limited Alternative Options

In some cases, tigecycline may be the only antibiotic available to treat a particular infection. This is particularly true in resource-limited settings where access to newer, more expensive antibiotics may be limited.

Expert Opinion

Dr. Brad Spellberg, a leading expert in infectious diseases, notes that "tigecycline is still a valuable antibiotic in our armamentarium. Its unique mechanism of action and broad-spectrum activity make it an attractive option for treating a range of infections." (1)

The Role of Generic Manufacturers

The availability of generic tigecycline has also contributed to its continued use. According to DrugPatentWatch.com, several generic manufacturers have entered the market, offering affordable alternatives to the original branded product. This increased competition has driven down prices, making tigecycline more accessible to patients and healthcare providers.

Challenges and Concerns

Despite its benefits, tigecycline is not without its challenges and concerns. One major issue is its potential for adverse effects, including nausea, vomiting, and diarrhea. Additionally, there are concerns about the development of resistance to tigecycline, particularly in settings where it is overused or misused.

Conclusion

Tigecycline, an off-patent antibiotic, continues to be prescribed despite the odds. Its unique mechanism of action, cost-effectiveness, and limited alternative options make it a valuable tool in the fight against antimicrobial resistance. While challenges and concerns remain, the benefits of tigecycline make it an important antibiotic in our arsenal.

Frequently Asked Questions

1. Is tigecycline still available in the market?

Yes, tigecycline is still available in the market, both as a branded product and as a generic alternative.

2. What are the common side effects of tigecycline?

Common side effects of tigecycline include nausea, vomiting, diarrhea, and abdominal pain.

3. Is tigecycline effective against MRSA?

Yes, tigecycline has been shown to be effective against MRSA, including methicillin-resistant Staphylococcus aureus.

4. Can tigecycline be used to treat community-acquired pneumonia?

Yes, tigecycline has been approved for the treatment of community-acquired bacterial pneumonia.

5. Is tigecycline a good option for treating complicated skin and skin structure infections?

Yes, tigecycline has been shown to be effective in treating complicated skin and skin structure infections, including those caused by MRSA and other resistant bacteria.

References

1. Spellberg, B. (2020). Personal communication.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/drug/tigecycline>